P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS

• A. Kulasekararaj,
• W. Füreder,
• A. McDonald,
• J. L. R. Malherbe,
• S. Gandhi,
• D. Collins,
• M. Cornpropst,
• S. Dobo,
• M. K. Farmer,
• D. Kargl,
• W. Sheridan,
• M. Griffin,
• A. Risitano

Affiliations

A. Kulasekararaj

1 Kings College Hospital NHS Foundation Trust, London, United Kingdom

W. Füreder

2 Medical University of Vienna, Vienna, Austria

A. McDonald

3 Netcare Pretoria East Hospital, Moreleta Park

J. L. R. Malherbe

4 University of the Free State, Bloemfontein, South Africa

S. Gandhi

1 Kings College Hospital NHS Foundation Trust, London, United Kingdom

D. Collins

5 BioCryst Pharmaceuticals, Durham, United States of America

M. Cornpropst

5 BioCryst Pharmaceuticals, Durham, United States of America

S. Dobo

5 BioCryst Pharmaceuticals, Durham, United States of America

M. K. Farmer

5 BioCryst Pharmaceuticals, Durham, United States of America

D. Kargl

5 BioCryst Pharmaceuticals, Durham, United States of America

W. Sheridan

5 BioCryst Pharmaceuticals, Durham, United States of America

M. Griffin

6 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

A. Risitano

7 AORN Moscati, Avellino, Italy